Deutsche Bank AG Has $9.48 Million Stock Holdings in Akero Therapeutics, Inc. $AKRO

Key Points

• Deutsche Bank AG reduced its stake in Akero Therapeutics by 14.5%, selling 39,681 shares and owning 0.29% of the company worth approximately $9.48 million after the sale.
• Several large investors have recently altered their positions, with RTW Investments LP increasing their stake by 15.9% to own 6.86 million shares, valued at around $190.84 million.
• An insider, Catriona Yale, sold 10,000 shares for a total of $529,500, leading to a 9.85% decrease in their ownership, while analyst ratings on the stock have varied with a consensus rating of "Moderate Buy".

Deutsche Bank AG decreased its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 234,130 shares of the company's stock after selling 39,681 shares during the period. Deutsche Bank AG owned 0.29% of Akero Therapeutics worth $9,478,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. GF Fund Management CO. LTD. lifted its holdings in shares of Akero Therapeutics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,787 shares of the company's stock worth $72,000 after purchasing an additional 321 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Akero Therapeutics by 14.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,664 shares of the company's stock worth $114,000 after purchasing an additional 338 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Akero Therapeutics by 30.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock worth $67,000 after purchasing an additional 390 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of Akero Therapeutics by 19.0% in the 1st quarter. Amalgamated Bank now owns 2,570 shares of the company's stock worth $104,000 after purchasing an additional 410 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its holdings in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after purchasing an additional 450 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AKRO shares. TD Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating and a $76.00 price target on the stock. Citigroup lowered their target price on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Bank of America raised their target price on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research report on Tuesday, May 27th. Wall Street Zen upgraded Akero Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Cowen started coverage on Akero Therapeutics in a research report on Monday, August 4th. They issued a "buy" rating on the stock. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $81.57.

Akero Therapeutics Price Performance

Shares of AKRO traded up $0.35 during trading hours on Wednesday, hitting $47.95. 808,238 shares of the company were exchanged, compared to its average volume of 1,091,042. The company has a market capitalization of $3.84 billion, a PE ratio of -23.98 and a beta of -0.28. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.66 and a quick ratio of 12.66. The firm has a fifty day simple moving average of $51.59 and a 200-day simple moving average of $47.19. Akero Therapeutics, Inc. has a one year low of $21.34 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.11. During the same period in the prior year, the business earned ($0.81) EPS. As a group, sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Insider Buying and Selling at Akero Therapeutics

In other news, insider Timothy Rolph sold 12,500 shares of the firm's stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $49.30, for a total transaction of $616,250.00. Following the completion of the sale, the insider directly owned 167,124 shares of the company's stock, valued at $8,239,213.20. This trade represents a 6.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Cheng sold 30,000 shares of the firm's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $48.59, for a total value of $1,457,700.00. Following the completion of the sale, the chief executive officer directly owned 490,757 shares of the company's stock, valued at approximately $23,845,882.63. This trade represents a 5.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 230,406 shares of company stock worth $12,013,920. 7.07% of the stock is owned by insiders.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.